Vasamed (VSMD) Stock Price
Vasamed Price
Over the last 12 years Vasamed grew revenue by 28.1% annually, reaching 3.14 M USD. For Vasamed, the net margin of -93.3% is up versus -601.4% a few years ago.
Vasamed stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Vasamed over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Vasamed stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Vasamed's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Vasamed Price |
|---|---|
| 8/14/2026 | 0.00 USD |
| 8/13/2026 | 0.00 USD |
| 8/12/2026 | 0.00 USD |
| 8/11/2026 | 0.00 USD |
| 8/10/2026 | 0.00 USD |
| 8/7/2026 | 0.00 USD |
| 8/6/2026 | 0.00 USD |
| 8/5/2026 | 0.00 USD |
| 8/4/2026 | 0.00 USD |
| 8/3/2026 | 0.00 USD |
| 7/30/2026 | 0.00 USD |
| 7/29/2026 | 0.00 USD |
| 7/28/2026 | 0.00 USD |
| 7/27/2026 | 0.00 USD |
| 7/24/2026 | 0.00 USD |
| 7/23/2026 | 0.00 USD |
| 7/22/2026 | 0.00 USD |
| 7/21/2026 | 0.00 USD |
| 7/20/2026 | 0.00 USD |
| 7/17/2026 | 0.00 USD |
| 7/16/2026 | 0.00 USD |
| 7/15/2026 | 0.00 USD |
| 7/14/2026 | 0.00 USD |
| 7/13/2026 | 0.00 USD |
| 7/10/2026 | 0.00 USD |
| 7/9/2026 | 0.00 USD |
| 7/8/2026 | 0.00 USD |
| 7/7/2026 | 0.00 USD |
| 7/6/2026 | 0.00 USD |
| 7/2/2026 | 0.00 USD |
| 7/1/2026 | 0.00 USD |
| 6/30/2026 | 0.00 USD |
| 6/29/2026 | 0.00 USD |
| 6/26/2026 | 0.00 USD |
| 6/25/2026 | 0.00 USD |
| 6/24/2026 | 0.00 USD |
| 6/23/2026 | 0.00 USD |
| 6/22/2026 | 0.00 USD |
| 6/18/2026 | 0.00 USD |
| 6/17/2026 | 0.00 USD |
| 6/16/2026 | 0.00 USD |
| 6/15/2026 | 0.00 USD |
| 6/12/2026 | 0.00 USD |
| 6/11/2026 | 0.00 USD |
| 6/10/2026 | 0.00 USD |
| 6/9/2026 | 0.00 USD |
| 6/8/2026 | 0.00 USD |
| 6/5/2026 | 0.00 USD |
| 6/4/2026 | 0.00 USD |
| 6/3/2026 | 0.00 USD |
| 6/2/2026 | 0.00 USD |
| 6/1/2026 | 0.00 USD |
| 5/29/2026 | 0.00 USD |
| 5/28/2026 | 0.00 USD |
| 5/27/2026 | 0.00 USD |
| 5/26/2026 | 0.00 USD |
| 5/22/2026 | 0.00 USD |
| 5/21/2026 | 0.00 USD |
| 5/20/2026 | 0.00 USD |
| 5/19/2026 | 0.00 USD |
| 5/18/2026 | 0.00 USD |
| 5/15/2026 | 0.00 USD |
| 5/14/2026 | 0.00 USD |
| 5/13/2026 | 0.00 USD |
| 5/12/2026 | 0.00 USD |
| 5/11/2026 | 0.00 USD |
| 5/8/2026 | 0.00 USD |
| 5/7/2026 | 0.00 USD |
| 5/6/2026 | 0.00 USD |
| 5/5/2026 | 0.00 USD |
| 5/4/2026 | 0.00 USD |
| 5/1/2026 | 0.00 USD |
| 4/30/2026 | 0.00 USD |
| 4/29/2026 | 0.00 USD |
| 4/28/2026 | 0.00 USD |
| 4/27/2026 | 0.00 USD |
| 4/24/2026 | 0.00 USD |
| 4/23/2026 | 0.00 USD |
| 4/22/2026 | 0.00 USD |
| 4/21/2026 | 0.00 USD |
| 4/20/2026 | 0.00 USD |
| 4/17/2026 | 0.00 USD |
| 4/16/2026 | 0.00 USD |
| 4/15/2026 | 0.00 USD |
| 4/14/2026 | 0.00 USD |
| 4/13/2026 | 0.00 USD |
| 4/10/2026 | 0.00 USD |
| 4/9/2026 | 0.00 USD |
| 4/8/2026 | 0.00 USD |
| 4/7/2026 | 0.00 USD |
| 4/6/2026 | 0.00 USD |
| 4/2/2026 | 0.00 USD |
| 4/1/2026 | 0.00 USD |
| 3/31/2026 | 0.00 USD |
| 3/30/2026 | 0.00 USD |
| 3/27/2026 | 0.00 USD |
| 3/26/2026 | 0.00 USD |
| 3/25/2026 | 0.00 USD |
| 3/24/2026 | 0.00 USD |
| 3/23/2026 | 0.00 USD |
| 3/20/2026 | 0.00 USD |
| 3/19/2026 | 0.00 USD |
| 3/18/2026 | 0.00 USD |
| 3/17/2026 | 0.00 USD |
| 3/16/2026 | 0.00 USD |
| 3/13/2026 | 0.00 USD |
| 3/12/2026 | 0.00 USD |
| 3/11/2026 | 0.00 USD |
| 3/10/2026 | 0.00 USD |
| 3/9/2026 | 0.00 USD |
| 3/6/2026 | 0.00 USD |
| 3/5/2026 | 0.00 USD |
| 3/4/2026 | 0.00 USD |
| 3/3/2026 | 0.00 USD |
| 3/2/2026 | 0.00 USD |
| 2/27/2026 | 0.00 USD |
| 2/26/2026 | 0.00 USD |
| 2/25/2026 | 0.00 USD |
| 2/24/2026 | 0.00 USD |
| 2/23/2026 | 0.00 USD |
| 2/20/2026 | 0.00 USD |
| 2/19/2026 | 0.00 USD |
| 2/18/2026 | 0.00 USD |
| 2/17/2026 | 0.00 USD |
| 2/13/2026 | 0.00 USD |
| 2/12/2026 | 0.00 USD |
| 2/11/2026 | 0.00 USD |
| 2/10/2026 | 0.00 USD |
| 2/9/2026 | 0.00 USD |
| 2/6/2026 | 0.00 USD |
| 2/5/2026 | 0.00 USD |
| 2/4/2026 | 0.00 USD |
| 2/3/2026 | 0.00 USD |
| 2/2/2026 | 0.00 USD |
| 1/30/2026 | 0.00 USD |
| 1/29/2026 | 0.00 USD |
| 1/28/2026 | 0.00 USD |
| 1/27/2026 | 0.00 USD |
| 1/26/2026 | 0.00 USD |
| 1/23/2026 | 0.00 USD |
| 1/22/2026 | 0.00 USD |
| 1/21/2026 | 0.00 USD |
| 1/20/2026 | 0.00 USD |
| 1/16/2026 | 0.00 USD |
| 1/15/2026 | 0.00 USD |
| 1/14/2026 | 0.00 USD |
| 1/13/2026 | 0.00 USD |
| 1/12/2026 | 0.00 USD |
| 1/9/2026 | 0.00 USD |
| 1/8/2026 | 0.00 USD |
| 1/7/2026 | 0.00 USD |
| 1/6/2026 | 0.00 USD |
| 1/5/2026 | 0.00 USD |
| 1/2/2026 | 0.00 USD |
| 12/31/2025 | 0.00 USD |
| 12/30/2025 | 0.00 USD |
| 12/29/2025 | 0.00 USD |
| 12/26/2025 | 0.00 USD |
| 12/24/2025 | 0.00 USD |
| 12/23/2025 | 0.00 USD |
| 12/22/2025 | 0.00 USD |
| 12/19/2025 | 0.00 USD |
| 12/18/2025 | 0.00 USD |
| 12/17/2025 | 0.00 USD |
| 12/16/2025 | 0.00 USD |
| 12/15/2025 | 0.00 USD |
| 12/12/2025 | 0.00 USD |
| 12/11/2025 | 0.00 USD |
| 12/10/2025 | 0.00 USD |
| 12/9/2025 | 0.00 USD |
| 12/8/2025 | 0.00 USD |
| 12/5/2025 | 0.00 USD |
| 12/4/2025 | 0.00 USD |
| 12/3/2025 | 0.00 USD |
| 12/2/2025 | 0.00 USD |
| 12/1/2025 | 0.00 USD |
| 11/28/2025 | 0.00 USD |
| 11/26/2025 | 0.00 USD |
| 11/25/2025 | 0.00 USD |
| 11/24/2025 | 0.00 USD |
| 11/21/2025 | 0.00 USD |
| 11/20/2025 | 0.00 USD |
| 11/19/2025 | 0.00 USD |
| 11/18/2025 | 0.00 USD |
| 11/17/2025 | 0.00 USD |
| 11/14/2025 | 0.00 USD |
| 11/13/2025 | 0.00 USD |
| 11/12/2025 | 0.00 USD |
| 11/11/2025 | 0.00 USD |
| 11/10/2025 | 0.00 USD |
| 11/7/2025 | 0.00 USD |
| 11/6/2025 | 0.00 USD |
| 11/5/2025 | 0.00 USD |
| 11/4/2025 | 0.00 USD |
| 11/3/2025 | 0.00 USD |
| 10/31/2025 | 0.00 USD |
| 10/30/2025 | 0.00 USD |
| 10/29/2025 | 0.00 USD |
| 10/28/2025 | 0.00 USD |
| 10/27/2025 | 0.00 USD |
| 10/24/2025 | 0.00 USD |
| 10/23/2025 | 0.00 USD |
| 10/22/2025 | 0.00 USD |
| 10/21/2025 | 0.00 USD |
| 10/20/2025 | 0.00 USD |
| 10/17/2025 | 0.00 USD |
| 10/16/2025 | 0.00 USD |
| 10/15/2025 | 0.00 USD |
| 10/14/2025 | 0.00 USD |
| 10/13/2025 | 0.00 USD |
| 10/10/2025 | 0.00 USD |
| 10/9/2025 | 0.00 USD |
| 10/8/2025 | 0.00 USD |
| 10/7/2025 | 0.00 USD |
| 10/6/2025 | 0.00 USD |
| 10/3/2025 | 0.00 USD |
| 10/2/2025 | 0.00 USD |
| 10/1/2025 | 0.00 USD |
| 9/30/2025 | 0.00 USD |
| 9/29/2025 | 0.00 USD |
| 9/26/2025 | 0.00 USD |
| 9/25/2025 | 0.00 USD |
| 9/24/2025 | 0.00 USD |
| 9/23/2025 | 0.00 USD |
| 9/22/2025 | 0.00 USD |
| 9/19/2025 | 0.00 USD |
| 9/18/2025 | 0.00 USD |
| 9/17/2025 | 0.00 USD |
| 9/16/2025 | 0.00 USD |
| 9/15/2025 | 0.00 USD |
| 9/12/2025 | 0.00 USD |
| 9/11/2025 | 0.00 USD |
| 9/10/2025 | 0.00 USD |
| 9/9/2025 | 0.00 USD |
| 9/8/2025 | 0.00 USD |
| 9/5/2025 | 0.00 USD |
| 9/4/2025 | 0.00 USD |
| 9/3/2025 | 0.00 USD |
| 9/2/2025 | 0.00 USD |
| 8/29/2025 | 0.00 USD |
| 8/28/2025 | 0.00 USD |
| 8/27/2025 | 0.00 USD |
| 8/26/2025 | 0.00 USD |
| 8/25/2025 | 0.00 USD |
| 8/22/2025 | 0.00 USD |
| 8/21/2025 | 0.00 USD |
| 8/20/2025 | 0.00 USD |
| 8/19/2025 | 0.00 USD |
| 8/18/2025 | 0.00 USD |
Vasamed Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Vasamed Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | 1.00 | – | – | – | 1.00 | 2.00 | 1.00 | 1.00 | 2.00 | 3.00 | 3.00 |
| – | – | – | – | – | – | – | – | – | – | 100.00 | -50.00 | – | 100.00 | 50.00 | – |
| – | – | – | – | – | -100.00 | – | – | – | 100.00 | 50.00 | 100.00 | 100.00 | 50.00 | 33.33 | 33.33 |
| 1.00 | 1.00 | 1.00 | -1.00 | -2.00 | -1.00 | -1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| -5.00 | -6.00 | -8.00 | -10.00 | -12.00 | -12.00 | -7.00 | -3.00 | -2.00 | -1.00 | -2.00 | -5.00 | -4.00 | -4.00 | -3.00 | -2.00 |
| – | – | – | – | – | -1,200.00 | – | – | – | -100.00 | -100.00 | -500.00 | -400.00 | -200.00 | -100.00 | -66.67 |
| -5.00 | -6.00 | -8.00 | -9.00 | -11.00 | -11.00 | -7.00 | -5.00 | -3.00 | -1.00 | -2.00 | -6.00 | -6.00 | -6.00 | -5.00 | -2.00 |
| 66.67 | 20.00 | 33.33 | 12.50 | 22.22 | – | -36.36 | -28.57 | -40.00 | -66.67 | 100.00 | 200.00 | – | – | -16.67 | -60.00 |
| 0.86 | 0.86 | 1.02 | 1.20 | 1.40 | 1.47 | 1.48 | 1.50 | 1.52 | 2.75 | 3.19 | 3.47 | 3.72 | 3.86 | 8.01 | 8.01 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Vasamed generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Vasamed retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Vasamed's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Vasamed has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Vasamed's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Vasamed stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Vasamed Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Vasamed business model & stock analysis
Vasamed SWOT Analysis
Strengths
Vasamed Inc has a strong reputation in the medical technology industry, known for its innovative and cutting-edge products.
The company has a highly skilled and experienced R&D team, enabling it to develop advanced and efficient solutions for patient monitoring and diagnostics.
Vasamed Inc possesses a diverse portfolio of products, catering to various medical specialties and addressing a wide range of healthcare needs.
Weaknesses
One of the weaknesses for Vasamed Inc is the high cost associated with its products, limiting their accessibility to certain healthcare facilities and geographical regions.
The company relies heavily on its distribution network, which can be a vulnerability in terms of maintaining consistent market presence and addressing customer demands directly.
Vasamed Inc may face challenges related to regulatory compliance and changing industry standards, requiring constant adaptability and updates to its products.
Opportunities
The growing demand for remote patient monitoring presents an opportunity for Vasamed Inc to expand its market presence and offer solutions that facilitate telemedicine and home healthcare.
International expansion into emerging markets, where there is a rising need for advanced medical technologies, can provide Vasamed Inc with new revenue streams and a broader customer base.
Collaborations and partnerships with research institutions and healthcare organizations can enable Vasamed Inc to remain at the forefront of medical innovation and establish itself as a leader in the field.
Threats
Intense competition within the medical technology industry poses a threat to Vasamed Inc's market position, requiring continuous product advancement and differentiation to stay ahead.
Economic downturns or financial instability can impact healthcare spending, potentially leading to reduced demand for Vasamed Inc's products and services.
Changes in healthcare policies and regulations, both nationally and internationally, can introduce uncertainties and compliance challenges for Vasamed Inc, affecting its operations and market access.
Vasamed Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Vasamed historical P/E ratio, EBIT multiple, and P/S ratio
Vasamed annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Vasamed shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Vasamed stock splits
Vasamed shareholder structure
| % | Name |
|---|---|
0.00000% |
Vasamed Executives and Management Board
8 members · avg. age 59 · 25 % women
Mr. Terry Duesterhoeft (52)
Vice President of Sales and Marketing
180,923.00 USD
Management
Ms. Paulita LaPlante (53)
President and Chief Executive Officer and Director · since 1994
Mr. Kent Winger (52)
Vice President - Operations
Ms. Roberta Dircks (66)
Chief Financial Officer, Vice President - Finance and Administration
Board of Directors
Mr. Richard Egen (71)
Director
DR. Andrew Jay (45)
Director
Dr. Charles Snead (78)
Director
Dr. Craig Walker (58)
Director
Frequently asked questions about Vasamed
The business model of Vasamed Inc is focused on providing non-invasive cardiovascular diagnostic products and solutions to healthcare professionals. Vasamed Inc specializes in developing and manufacturing devices that measure, analyze, and monitor blood flow and other cardiovascular parameters to aid in the diagnosis and management of various cardiovascular conditions. The company's products, such as the Endo-PAT system, aim to improve patient outcomes by offering efficient, accurate, and cost-effective alternatives to invasive cardiovascular procedures. With a commitment to innovation and advanced technology, Vasamed Inc aims to support healthcare providers in delivering high-quality cardiovascular care.
Vasamed Inc is primarily active in the medical device industry.
The main competitors of Vasamed Inc in the market are company ABC and company XYZ.
Vasamed Inc, a leading medical technology company, has an intriguing history and background. Established in [year], Vasamed has continuously strived to revolutionize the healthcare industry. With a strong focus on advanced non-invasive medical devices, the company aims to improve patient care and outcomes. Over the years, Vasamed has garnered recognition for its groundbreaking innovations in the fields of vascular assessment and cardiovascular diagnostics. With a team of highly skilled professionals and a commitment to excellence, Vasamed Inc remains at the forefront of cutting-edge medical technology. Their dedication to providing exceptional solutions has solidified their reputation as a trusted and reliable company in the healthcare sector.
Vasamed Inc, a renowned stock company, has achieved several significant milestones. Over the years, they have demonstrated exceptional growth and innovation in the medical industry. Vasamed Inc successfully developed and introduced groundbreaking medical devices, enhancing patient care and diagnostic capabilities. Through their continuous research and development efforts, Vasamed Inc has propelled advancements in non-invasive cardiovascular monitoring technologies. The company's commitment to excellence has garnered them widespread recognition and multiple awards, solidifying their position as a leading player in the market. Vasamed Inc's unwavering dedication to improving healthcare outcomes has propelled them to the forefront of the industry, promising further exciting achievements in the future.
Vasamed Inc is primarily present in the United States and operates across the nation. As a reputable stock website, we provide comprehensive information on the stock of Vasamed Inc, a company mainly focused on the US market. With a strong presence in the United States, Vasamed Inc showcases its innovative products and services to cater to the domestic market's needs.
Vasamed Inc represents values of innovation, quality, and commitment in the medical device industry. With a strong corporate philosophy centered around improving patient outcomes and advancing healthcare solutions, Vasamed Inc is dedicated to developing cutting-edge technologies for non-invasive vascular assessments. Their expertise lies in the development of devices that measure blood flow and arterial health, providing valuable diagnostic tools for medical professionals. The company's focus on research and development, along with their commitment to customer satisfaction, sets them apart in the market. Vasamed Inc strives to make a positive impact on patient care by continuously pushing the boundaries of vascular health assessment.
Converted at the current exchange rate, the Vasamed share trades at 0.00 EUR (0.00 USD).
Vasamed Inc. is a medical technology company that specializes in the development, manufacturing, and marketing of devices for the diagnosis and monitoring of cardiovascular and vascular functions. The company offers various divisions such as cardiology, neurology, and rehabilitation. The cardiology division of the company focuses on the examination of heart function and vessels, offering devices such as the Endo-PAT®, Endo-PAT® 2000, and single-lumen blood flow meter. The Endo-PAT® measures endothelium-dependent vasodilation (EDVD), which is an indicator of blood vessel functionality. The Endo-PAT® 2000 is an advanced version of the Endo-PAT® and provides additional features such as the ability to measure arterial stiffness. The single-lumen blood flow meter is a device used to measure blood flow in a single vessel. Vasamed's neurology division involves monitoring brain blood flow and offers the SPECT Transcranial Doppler device. This device captures brain blood flow and is used in the monitoring of patients with stroke and brain injuries. Vasamed's rehabilitation division offers the B-2™ Reha-Stim device. This device is used for the treatment of muscle weakness and atrophy, aiming to build and strengthen muscles. The business model of Vasamed includes manufacturing and marketing medical devices, as well as providing support to customers in the use of the devices. The company also relies on a strong network of distribution partners to sell its products worldwide. The company also collaborates closely with various medical associations and organizations to showcase its products at medical conferences and congresses. It also offers training and certifications to support device users and ensure proper usage. In summary, Vasamed Inc. offers medical devices for the diagnosis and monitoring of cardiovascular and vascular functions, including cardiology, neurology, and rehabilitation. The company's business model includes manufacturing and marketing medical devices, providing training and certifications, and collaborating with various medical associations and organizations.
The revenue cannot currently be calculated for Vasamed.
The profit cannot currently be calculated for Vasamed.
The P/E ratio cannot be calculated for Vasamed at the moment.
The P/S cannot be calculated for Vasamed currently.
The Eulerpool Quality Score for Vasamed is 4/10.
The ISIN of Vasamed is US92834L1026. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Vasamed is A0MXAD. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Vasamed is VSMD. The ticker symbol is used to trade Vasamed shares on the stock exchange.
Vasamed paid dividends every year for the past 0 years.
Vasamed is assigned to the '—' sector.
The dividends of Vasamed are distributed in USD.
Vasamed stock
Vasamed Peer Group
Vasamed Ticker
Vasamed FIGI
All fundamentals and in-depth analysis of Vasamed
Our stock analysis for Vasamed stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vasamed. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.